Andecaliximab

Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF)[1][2].

Research Areas >> Cancer

Signaling Pathways >> Metabolic Enzyme/Protease >> MMP

Andecaliximab 增加血清中 IL-7 的水平[1]。 Andecaliximab (50 μg/mL；24 h)减少 ABC 类细胞系的 SMAD2 磷酸化 (pSMAD2)[2]。

Andecaliximab 改善肿瘤浸润 T 细胞内 T 细胞受体 (TCR) 的多样性[1]。 Andecaliximab (20 mg/kg；腹腔注射，单次) 在特发性肺纤维化的人源 NSG 小鼠模型中显示出抗纤维化功效[2]。 Animal Model: Humanized nonobese diabetic, SCID, IL-2 receptor g (NSG) mouse model of IPF[2] Dosage: 20 mg/kg Administration: Intraperitoneal injection; 20 mg/kg, once a week for once Result: Decreased SMAD2 phosphorylation and increased surfactant protein C. Reduced MMP9+ cells, including MMP9+, CCR10+ and MMP9+CD45- and EpCAM+CCR10+ subpopulations.

[1]. Andrew E. Greenstein, et al. Effect of andecaliximab (anti-MMP9) on proteolysis of IL-7 in vitro, TCR diversity in mice, and serum IL-7 in gastric cancer patients in combination with chemotherapy. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium.

[2]. Espindola MS, et al. Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 Feb 15;203(4):458-470.